ClinicalTrials.gg
CompletedNCT04269031Updated Jul 10, 2023

A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

A Phase 1 interventional study of AZD2373 subcutaneous injection and Placebo in Healthy Volunteers, sponsored by AstraZeneca. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-10.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2021, 5 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a Phase 1 study to assess the the safety, tolerability and pharmacokinetics (PK) of AZD2373, following subcutaneous (SC) administration of single ascending doses (SAD) of AZD2373 in healthy male subjects of African ancestry.

Read the detailed description

This study will be conducted as a single-centre, randomised, placebo-controlled, single-blind study to assess the effect of AZD2373 following ascending dose sequential group design administrations to healthy male subjects of African ancestry. The study will include 6 single dose cohorts with the option to include 2 additional cohorts based on emerging data from preceding cohorts in the study.

Approximately 48 male subjects aged 18 to 55 years at the time of informed consent (inclusive) will be randomized with the aim to have 8 subjects participate in each cohort. Within each cohort, 6 subjects will receive AZD2373 and 2 subjects will receive placebo.

Sentinel dosing will be applied for each cohort and will be divided into 2 groups:

  • Group 1 (sentinel group): 1 active, 1 placebo;
  • Group 2 (the rest of the cohort): 5 active, 1 placebo. The safety data of up to 72 hours post-dose in Group 1 will be reviewed by the Principal Investigator (PI) before the subjects in Group 2 are dosed.

The study will comprise:

  • A Screening Period of maximum 35 days;
  • A Treatment Period during which subjects will be resident at the Clinical Unit from the day before investigational medicinal product (IMP) administration (Day -1) until at least 72 hours after IMP administration; discharged from the Clinical Unit on Day 4;
  • Follow-up Visits on 1, 1.5, 2, 3, 4, 5, 6, and 8 weeks (Visits 3 to 10); and
  • A Final Follow up Visit 10 weeks after the last IMP dose.

The visit occurring at 5 weeks post dose (Visit 5) is optional. The expected duration for any subject participating in the study is approximately 10 weeks (excluding an up to 28-day Screening Period).

02

Conditions studied

  • Healthy Volunteers

Keywords

  • First-in-Human
  • Randomized
  • Single-blind
  • Placebo controlled
  • AZD2373
  • Single Ascending Dose
  • Sentinel Dosing
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written prior to any study specific procedures.
  • Healthy male subjects of West African ancestry aged 18 to 55 years (inclusive, at time of informed consent) with suitable veins for cannulation or repeated venipuncture.
  • Have a (BMI) between 18 and 35 kg/m\^2 (inclusive) and weigh at least 50 kg and no more than 120 kg (inclusive).
  • Provision of signed, written and dated informed consent for study participation which includes mandatory genotyping (study objective). NOTE: If a subject would decline to participate in the mandatory genotyping component of the study, the subject will not be included in the study.

Exclusion criteria

Exclusion Criteria:

  • Subjects with known ancestry outside of West Africa.
  • History of any disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
  • History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure or trauma within 4 weeks prior to administration of IMP on Study Day 1.
  • Any laboratory values with the following deviations:

    1. or aspartate aminotransferase greater than and clinically significant as determined by the PI.
    2. White blood cell (WBC) count \< 3.0 x 10\^9/L.
    3. (Hb) below lower limit normal .
  • Any clinically important abnormalities in clinical chemistry, hematology or urinalysis results, other than those described above, as judged by the PI.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Cohort 1

    On Day 1, randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 1 (6 subjects) or matching placebo (2 subjects).

    Drug: AZD2373 subcutaneous injection · Drug: Placebo

  • Experimental
    Cohort 2

    On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 2 (6 subjects) or matching placebo (2 subjects).

    Drug: AZD2373 subcutaneous injection · Drug: Placebo

  • Experimental
    Cohort 3

    On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 3 (6 subjects) or matching placebo (2 subjects).

    Drug: AZD2373 subcutaneous injection · Drug: Placebo

  • Experimental
    Cohort 4

    On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 4 (6 subjects) or matching placebo (2 subjects).

    Drug: AZD2373 subcutaneous injection · Drug: Placebo

  • Experimental
    Cohort 5

    On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 5 (6 subjects) or matching placebo (2 subjects).

    Drug: AZD2373 subcutaneous injection · Drug: Placebo

  • Experimental
    Cohort 6

    On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 6 (6 subjects) or matching placebo (2 subjects).

    Drug: AZD2373 subcutaneous injection · Drug: Placebo

Interventions

  • Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).

  • DrugPlacebo

    Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.

06

What researchers measure

Primary outcomes

  1. Number of subjects with adverse events and/or abnormal findings in vital signs, and/or clinical laboratory assessments and/or physical examination and/or electrocardiogram (ECG) evaluation and/or telemetry and/or injection site reactions

    To assess adverse events as a variable of safety and tolerability of subcutaneous (SC) single ascending dose (SAD) administrations of AZD2373

    Time frame: Screening Visit to final Follow-up Visit (Week 10 post last dose)

Secondary outcomes

  1. Area under plasma concentration-time curve from time zero extrapolated to infinity (AUC)

    To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

  2. Area under the plasma concentration curve from time zero to the time of last quantifiable analyte concentration (AUClast)

    To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

  3. Area under the plasma concentration-time curve from time zero to 72 hours after dosing [AUC(0-72)]

    To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

  4. Area under the plasma concentration-time curve from time zero to 48 hours after dosing [AUC (0-48)]

    To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

  5. Observed maximum plasma concentration (Cmax)

    To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

  6. Time to reach peak or maximum observed concentration or response following drug administration (tmax)

    To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

  7. Half-life associated with terminal slope (λz) of a semi logarithmic concentration-time curve (t½λz)

    To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

  8. Apparent total body clearance of drug from plasma after extravascular administration [CL/F]

    To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

  9. Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)

    To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

  10. Mean residence time of the unchanged drug in the systemic circulation (MRT)

    To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

  11. Terminal elimination rate constant (λz)

    To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

  12. Time of the last quantifiable concentration [tlast Ae(0-last)]

    To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

  13. Cumulative fraction (%) of dose excreted unchanged into the urine from time zero to the last measured time point [fe(0-last)]

    To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

  14. Amount of analyte excreted into the urine from time t1 to t2 [Ae(t1-t2)]

    To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

  15. Fraction of dose excreted unchanged into the urine from time t1 to t2 [fe(t1-t2)]

    To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

  16. Renal clearance of drug from plasma, estimated by dividing Ae(0-t) by AUC(0-t) where the 0-t interval is the same for both Ae and AUC (CLR)

    To characterize the PK of AZD2373 following SC SAD administrations of AZD2373.

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

  17. Apolipoprotein L1 (APOL1) concentrations and change from baseline

    To assess the effect of SC SAD administrations of AZD2373 on plasma concentrations of APOL1 protein

    Time frame: Visit 2 to final Follow-up Visit (Week 10 post last dose)

07

Study locations

1 site
  • Research Site
    Brooklyn, Maryland 21225, United States
08

References and documents

Publications

  • Bruggeman LA, Sedor JR, O'Toole JF. Apolipoprotein L1 and mechanisms of kidney disease susceptibility. Curr Opin Nephrol Hypertens. 2021 May 1;30(3):317-323. doi: 10.1097/MNH.0000000000000704. PubMed 33767059 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Aug 2021, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2020
First posted
Feb 13, 2020
StartActual
Feb 13, 2020
Primary completionActual
Aug 31, 2021
CompletionActual
Aug 31, 2021
Last update
Jul 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04269031
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Feb 13, 2020
Start date
Feb 13, 2020
Primary completion
Aug 31, 2021
Completion
Aug 31, 2021
Last update
Jul 10, 2023

Study contacts

Ronald Goldwater, Dr.
principal investigator · PAREXEL Early Phase Clinical Unit Baltimore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Opemalirsen

Start the discussion